FDA 510(k) EXEMPTION OF 62 CLASS II DEVICES ON JAN. 21 BRINGS TOTAL TO 636; RULE INCLUDES 30 IVDs, BUT DOES NOT APPLY TO POINT-OF-CARE TEST SYSTEMS
This article was originally published in The Gray Sheet
FDA exemption of 62 Class II devices from 510(k) review in a Jan. 21 final rule brings to 636 the total number of products that no longer require premarket evaluation. The final rule was published two days after the 60-day deadline stipulated in the FDA Modernization Act, which was signed into law Nov. 21.
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.